

Clinical studies with **Viscoseal[®]** following arthroscopic surgery



viscoseal[®]



Clinical studies with Viscoseal® in arthroscopic surgery (442 patients)

□ Shoulder

Funk L. *et al.* 9th OARSI Congress. 2004 (poster) (58 patients)

Cohen D.R. *et al.* 8th EFORT Congress. 2007 (abstract) (20 patients)

□ Knee

Anand S. *et al.* 9th OARSI Congress. 2004 (poster) (48 patients)

Villamor A. *et al.* 9th OARSI Congress. 2004 (poster) (93 patients)

Mathies B. *Knee Surg Sports Traumatol Arthrosc.* 2007; 14(1): 32-9 (50 patients)

Hempfling H. *Knee Surg Sports Traumatol Arthrosc.* 2007; 15(5): 537-46 (80 patients)

Perez-Caballer A. *et al.* 8th EFORT Congress. 2007 (abstract) (93 patients)

Funk L., Wykes P.R.

Manchester, UK

viscoseal®

**Synovial fluid replacement in
arthroscopic shoulder surgery –
a randomised, prospective, controlled
trial**

9th Congress of the Osteoarthritis Research Society International
Chicago, USA, December 2-5, 2004 (poster)




Study design

- Prospective, open, randomised, controlled study
- 58 patients undergoing **subachromial** decompression
- Treatment (n = 58 shoulders):
 - **Viscoseal® group** (n = 28): standard arthroscopy + i.a. sodium hyaluronate 50 mg/10 ml + 0.5% bupivacaine 10 ml
 - **Control group** (n = 30): standard arthroscopy + i.a. 0.5% bupivacaine 20 ml
- Immediate post-operative follow-up (4 hours)




Pain at 4 hours post-op





Analgesics required within first 4 hours post-op





Discharge from hospital

- Viscoseal[®] group: 5.2 ± 1.3 hours
- Control group: 9.6 ± 5.3 hours
- $p = 0.0001$

Cohen D.R., Olivier O., Jahraja H.A., Kemp G., Hunter J.,
Waseem M.

Macclesfield, UK

viscoseal®

Synovial fluid replacement in arthroscopic shoulder surgery

8th Congress of the European Federation of National Associations of
Orthopedics and Traumatology

Florence, Italy, May 11-15, 2007 (abstract)



Study design

- Prospective, double blind, randomised, controlled study
- 20 patients undergoing **subachromial** decompression
- Treatment (n = 20 shoulders):
 - **Viscoseal® group** (n = 10): standard arthroscopy
+ i.a. sodium hyaluronate 50 mg/10 ml
+ 0.5% bupivacaine 10 ml
 - **Control group** (n = 10): standard arthroscopy
+ i.a. diamorphine 10 mg/10 ml
+ 0.5% bupivacaine 10 ml
- 24 hour follow-up (1, 2, 6, 12 and 24 hours post-operative)



Results

Parameter	Viscoseal®	Control	p value*
Early discharge (<i>i.e.</i> , on the same day)	40%	0%	0.054
Pain score (VAS)	8%*	ns	> 0.08
Fraction of patients with no pain			> 0.08
Supplementary analgesic drug consumption			> 0.08
Fraction of patients with no pain			> 0.08
Nausea	10%	60%	0.03

* Fischer's exact test

Anand S., Mitchell S., Bamforth C., Asumu T., Buch K.A.
Oldham, UK

viscoseal®

**Effect of sodium hyaluronate on
recovery after arthroscopic knee
surgery –
a randomised controlled study**

9th Congress of the Osteoarthritis Research Society International
Chicago, USA, December 2-5, 2004 (poster)




Study design

- Prospective, double-blind, randomised, controlled study
- 48 patients with clinical indication for **knee** arthroscopy
- Treatment (n = 48 knees):
 - **Viscoseal® group** (n = 24): standard arthroscopy + i.a. sodium hyaluronate 50 mg/10 ml
 - **Control group** (n = 24): standard arthroscopy + i.a. 0.5% bupivacaine 10 ml
- 6 week follow-up




Pain at rest (0-10 cm)






Pain on movement (0-10 cm)






Pain on weight bearing (0-10 cm)





Total WOMAC (0-96)





Other secondary efficacy parameters

- Viscoseal[®] significantly improved the SF-12 compared to bupivacaine.
- Analgesic consumption was significantly reduced at weeks 3 and 6 in favour of Viscoseal[®].



Conclusions

- Synovial fluid replacement after arthroscopic knee surgery offers significantly improved function and pain relief over the medium term (3-6 weeks).

Villamor A. *et al.*
Madrid, Spain

viscoseal®

**Viscoseal® aids recovery after
arthroscopy –
a single-blind, randomised,
multicentre study**

9th Congress of the Osteoarthritis Research Society International
Chicago, USA, December 2-5, 2004 (poster)




Study design

- Prospective, single-blind, randomised, controlled study
- 93 patients requiring partial meniscectomy and/or osteochondral debridement of the **knee**
- Treatment (n = 93 knees):
 - **Viscoseal® group** (n = 48): standard arthroscopy + i.a. sodium hyaluronate 50 mg/10 ml
 - **Control group** (n = 45): standard arthroscopy
- 28 day follow-up



Pain scores (0-100 mm)





Conclusions

- The results suggest that Viscos seal[®] accelerates post-arthroscopy recovery during this period by reducing pain and discomfort, and increasing the mobility of the affected knee.

Mathies B.

Geneva, Switzerland

Effects of Viscoseal[®], a synovial fluid substitute, on recovery after arthroscopic partial meniscectomy and joint lavage

viscoseal[®]

Knee Surgery, Sports Traumatology and Arthroscopy

Vol. 14, No. 1, p. 32-39, January 2006



Study design

- Prospective, single-blind, randomised, controlled pilot study
- 50 patients with evidence of meniscal pathology (MRI) requiring **knee** arthroscopic intervention
- Treatment (n = 50 knees):
 - **Viscoseal[®] group** (n = 25): standard arthroscopy + i.a. sodium hyaluronate 50 mg/10 ml
 - **Control group** (n = 25): standard arthroscopy
- 1 month follow-up




Evaluation parameters

□ Efficacy Parameters

- Pain at rest (100 mm VAS)
- (Pain on squatting (100 mm VAS))
- Consumption of escape medication
- Lysholm score
- Daily activities (MODEMS)
- Swelling
- Efficacy judgement by the patient (5 point scale)
- Efficacy judgement by the doctor (5 point scale)




Pain at rest (0-100 mm)






Pain on squatting (0-100 mm)





Statistical analyses for swelling

(97.5% CI, one-sided)




0.29 / 0.71 = large difference; 0.36 / 0.64 = medium-sized difference; 0.44 / 0.56 = small difference; 0.50 = equality



Statistical analyses for rescue medication consumption (97.5% CI, one-sided)


Rescue medication: diclofenac 50 mg tablets



0.29 / 0.71 = large difference; 0.36 / 0.64 = medium-sized difference; 0.44 / 0.56 = small difference; 0.50 = equality



Statistical analyses for patient's general evaluation (97.5% CI, one-sided)



0.29 / 0.71 = large difference; 0.36 / 0.64 = medium-sized difference; 0.44 / 0.56 = small difference; 0.50 = equality



Conclusions

- Globally the results showed that patients receiving Viscoséal[®] at the end of the arthroscopic procedure experienced less pain and improved joint function compared to those patients who received the standard procedure.
- Overall results seemed more to be in favour of Viscoséal[®] at days 7 and 12.

Hempfling H.

Murnau am Staffelsee, Germany

**Intra-articular hyaluronic acid after
knee arthroscopy:
a two-year study**

viscoseal®

Knee Surgery, Sports Traumatology and Arthroscopy

Vol. 15, No. 5, p. 537-546, May 2007




Study design

- Prospective, double-blind, randomised, controlled study
- 80 patients with severe **knee** joint pain in whom arthroscopic joint lavage (+ intra-operative cartilage smoothing) was indicated
- Treatment (n = 80 knees):
 - **Viscoseal[®] group** (n = 40): standard arthroscopy + i.a. sodium hyaluronate 50 mg/10 ml
 - **Control group** (n = 40): standard arthroscopy
- 12 month follow-up




Pain on walking 100 m (0-100 mm)






Pain at night (0-100 mm)





Patient's clinical global impression





Conclusions

- Globally the results showed that patients receiving Viscoséal[®] at the end of the arthroscopic procedure experienced better long term results.
- Overall results seemed more to be in favour of Viscoséal[®] at months 3 and 12.
- The risk-benefit evaluation is in favour of Viscoséal[®].

Perez-Caballer A., Alcocer L., Macule F., Vaquero J. Villamor A.
Madrid, Spain

viscoseal®

Use of hyaluronic acid for the treatment of pain in knee arthroscopy

8th Congress of the European Federation of National Associations of
Orthopedics and Traumatology
Florence, Italy, May 11-15, 2007 (abstract)



Study design

- Prospective, multicentre, controlled study
- 93 patients requiring **knee** arthroscopic intervention
- Treatment (n = 93 knees):
 - **Viscoseal® group** (n = 48): standard arthroscopy + i.a. sodium hyaluronate 50 mg/10 ml
 - **Control group** (n = 45): standard arthroscopy
- 4 week follow-up



Results

Difference Viscoseal® vs control	1 week post-op	4 weeks post-op
Pain reduction	17%*	maintained
Reduction of other functional symptoms	8%*	ns
Area under the curve of pain (VAS)	39% lower for Viscoseal®	

No adverse events were reported.

* = significant; ns = non significant



Conclusions

- ❑ Significant decrease in knee pain in the first week after surgery.
- ❑ Significant reduction in sum of symptom scores.
- ❑ These results suggest that Viscoséal[®] accelerate post-arthroscopy recovery by reducing pain and discomfort, and increasing the mobility of the affected knee.